24. Jul 2026
Description
(AWP Alliance News) - Roche received FDA 510(k) clearance for its cobas BV/CV assay, expanding its sexual-health testing menu on the cobas 6800/8800 systems. The company is positioning the test to improve diagnostic accuracy in a high-volume women's health category where misdiagnosis is close to 50%, supporting faster, more targeted treatment decisions.
Roche aims to strengthen competitive differentiation by enabling broader sexual-health testing from a single sample, reducing repeat visits and simplifying lab workflows. The company expects a commercial launch later this year, with plans to add the cobas 5800 system under an FDA policy pathway.
https://www.prnewswire.com/news-releases/roche-receives-fda-clearance-f…
Disclaimer: This news brief was created using generative artificial intelligence. Roche Holding AG published the original content used to generate this news brief via PR Newswire on July 24, 2026, and is solely responsible for the information contained therein.
